

Pharmacy Formulary Updates for September 2021

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. The changes below are reflected in our online drug list.

The following is a list of drugs that changed formulary status in September 2021:

Drug Name	Tufts Health Plan Commercial Formularies						
	Massachusetts				Rhode Island		
	Large Group 3-Tier Formulary	Large Group 4-Tier Formulary	Small Group/ Individual 3-Tier (Exchange Formularies)	Small Group/ Individual 4-Tier (Exchange Formularies)	Large Group 3-Tier Formulary	Large Group 4-Tier Formulary	Small Group/ Individual 4-Tier (Exchange Formularies)
Lumakras (sotorasib)	Tier 2, PA, SP	Tier 4, PA, SP	Tier 2, PA, SP	Tier 4, PA, SP	Tier 2, PA	Tier 4, PA	Tier 4, PA
Rybrevant (amivantamab-vmjw)	MB						
Truseltiq (infigratinib)	Tier 2, PA	Tier 4, PA	Tier 2, PA	Tier 4, PA	Tier 2, PA	Tier 4, PA	Tier 4, PA
Artesunate IV solution	MB						
Nextstellis (drospirenone/estrol)	Tier 3, ACA						
Myfembree (relugolix-estradiol-norethindrone acetate)	Tier 3, PA, QL (30/30)						
Accrufer (ferric maltol)	NC						
Semglee (insulin glargine-yfgn)	NC						
Plaquenil	NC						

Key:

MM Managed Mail – must fill at mail order pharmacy

NC Not covered

PA Prior Authorization

QL Quantity Limitation

SP Specialty Pharmacy

ST^{PA} Step Therapy Prior Authorization

MB Medical Benefit

SI Specialty Infusion